Document is current
Any future updates will be listed below
-
Authors
Terheyden, Jan Henrik
Behning, Charlotte
Dunbar, Hannah M. P.
Poor, Stephen
Zakaria, Nadia
Binns, Alison M.
Saßmannshausen, Marlene
Leal, Sergio
Schmid, Matthias
Holz, Frank G.
Crabb, David P.
Luhmann, Ulrich F. O.
Finger, Robert P.
,
Agostini, H.
Aires, I. D.
Altay, L.
Atia, R.
Bandello, F.
Basile, P. G.
Batuca, J.
Behning, C.
Belmouhand, M.
Berger, M.
Binns, A.
Boon, C. J. F.
Böttger, M.
Brazier, J. E.
Carapezzi, C.
Carlton, J.
Carneiro, A.
Charil, A.
Coimbra, R.
Cosette, D.
Cozzi, M.
Crabb, D. P.
Cunha-Vaz, J.
Dahlke, C.
Dunbar, H.
Esposti, S.
Finger, R. P.
Fletcher, E.
Gutfleisch, M.
Hartgers, F.
Higgins, B.
Hildebrandt, J.
Höck, E.
Hogg, R.
Holz, F. G.
Hoyng, C. B.
Kilani, A.
Krätzschmar, J.
Kühlewein, L.
Larsen, M.
Leal, S.
Lechanteur, Y. T. E.
Luhmann, U. F. O.
Lüning, A.
Manivannan, N.
Marques, I.
Martinho, C.
Moll, K. P.
Mulyukov, Z.
Paques, M.
Parodi, B.
Parravano, M.
Penas, S.
Peters, T.
Peto, T.
Pfau, M.
Priglinger, S.
Ramamirtham, S.
Ribeiro, S.
Rowen, D.
Rubin, G. S.
Sahel, J.
Sánchez, C.
Sander, O.
Saßmannshausen, M.
Schmid, M.
Schmitz-Valckenberg, S.
Siedlecki, J.
Silva, R.
Souied, E.
Staurenghi, G.
Tavares, J.
Taylor, D. J.
Terheyden, J. H.
Tufail, A.
Valmaggia, P.
Varano, M.
Wolf, A.
Zakaria, N.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Bonn
- License Information
-
More Information
Article History
Received: 11 March 2025
Accepted: 31 July 2025
First Online: 9 October 2025
Declarations
:
: JHT: Beyer (C, F, R), Novartis (F, R), Roche (F), Okko (R) CB: None HMPD: Boehringer Ingelheim (C) SP: Novartis (E) NZ: Novartis (E) AMB: Apparatus and method for retinal measurement; Patent number 9492081 (P) MSa: Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), CenterVue (F) SL: Bayer (E) MSc: None FGH: Acucela (C, F), Allergan (F), Apellis (C, F), Bayer (C, F), Boehringer-Ingelheim (C), Bioeq/Formycon (C, F), CenterVue (F), Ellex (F), Roche/Genentech (C, F), Geuder (C, F), Graybug (C), Gyroscope (C), Heidelberg Engineering (C, F), IvericBio (C, F), Kanghong (C, F), LinBioscience (C), NightStarX (F), Novartis (C, F), Optos (F), Oxurion (C), Pixium Vision (C, F), Oxurion (C), Stealth BioTherapeutics (C), Zeiss (C, F) DPC: Apellis (C, F), Santen (F, R), Allergan/AbbVie (R), Thea (R), Janssen (S) UFOL: F.Hoffmann-La Roche. Ltd. (E) RPF: Bayer (C, F), Novartis (C, F), Roche/Genentech (C), Alimera (C), Böhringer-Ingelheim (C), Santhera (C), Ellex (C), Novartis (C, F), Zeiss (F), Heidelberg Engineering (F), CenterVue (F), Biogen (F).
: Ethical approval was obtained from the Institutional Review Boards of all involved centres and all participants gave written informed consent. The study protocol followed the principles of the Declaration of Helsinki.
: The communication reflects the author’s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.
